Get the Stockscreener App
1.11
5.93%
-0.07
After Hours:
1.10
-0.01
-0.90%
Immunic Inc stock is traded at $1.11, with a volume of 3.53M.
It is down -5.93% in the last 24 hours and down -5.13% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
See More
Previous Close:
$1.18
Open:
$1.08
24h Volume:
3.53M
Relative Volume:
1.04
Market Cap:
$144.82M
Revenue:
-
Net Income/Loss:
$-97.17M
P/E Ratio:
-1.4869
EPS:
-0.7465
Net Cash Flow:
$-85.97M
1W Performance:
-6.72%
1M Performance:
-5.13%
6M Performance:
+32.57%
1Y Performance:
+12.35%
1-Day Range:
$1.05
$1.13
1-Week Range:
$1.05
$1.34
52-Week Range:
$0.5062
$1.51
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
1.11 | 153.95M | 0 | -97.17M | -85.97M | -0.7465 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Initiated | Guggenheim | Buy |
| Nov-07-25 | Initiated | Roth Capital | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-25-25 | Initiated | William Blair | Outperform |
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
D. Boral Capital Initiates Immunic(IMUX.US) With Hold Rating - Moomoo
IMUX Downgraded by D. Boral Capital -- Rating Changed to Hold - GuruFocus
This Parsons Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
D. Boral Capital cuts Immunic stock rating on reverse split concerns - Investing.com Canada
Immunic Sets 1-for-10 Reverse Stock Split Plan - TipRanks
Immunic shareholders approve 1-for-10 reverse stock split, effective April 27 - Investing.com India
Shareholders back Immunic (NASDAQ: IMUX) 1-for-10 reverse stock split move - Stock Titan
Immunic (IMUX) price target increased by 16.67% to 5.36 - MSN
If You Invested $1,000 in Immunic Inc (IMUX) - Stock Titan
Immunic (HAM:10VA) PB Ratio : (As of Apr. 11, 2026) - GuruFocus
Immunic, Inc. CEO Daniel Vitt Enters Retention Bonus Agreement Amid Search for New Chief Executive Officer - Minichart
Immunic (NASDAQ: IMUX) begins CEO search, grants $670k retention bonus - Stock Titan
Immunic Inc Stock Baskets | HAM:10VA - GuruFocus
Immunic (IMUX) Price Target Decreased by 17.29% to 6.41 - MSN
Q3 2024 Immunic Inc Earnings Call Transcript - GuruFocus
Immunic to Participate in Scientific and Medical Conferences in April - ChartMill
Immunic to present lead MS therapy at April conferences - Proactive financial news
Insider Sell: Can Immunic Inc ride the EV waveQuarterly Earnings Report & Short-Term High Return Ideas - baoquankhu1.vn
Immunic, Inc. (IMUX) stock price, news, quote and history - Yahoo Finance UK
Immunic COO highlights the importance of science-led innovation to mark World Health Day - Proactive financial news
IMUX SEC FilingsImmunic Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Immunic to offer up to 458.2 million shares of common stock registered for resale by selling stockholdersSEC filing - marketscreener.com
Immunic To Offer Up To 458.2 Million Shares Of Common Stock Registered For Resale By Selling StockholdersSEC Filing - TradingView — Track All Markets
According to the latest filing with the U.S. Securities and Exchange Commission (SEC), the biopharmaceutical company Immunic, Inc. has initiated an equity resale program. - Bitget
Immunic (NASDAQ: IMUX) registers 458.2M resale shares after $200M private placement - Stock Titan
Immunic Regains Nasdaq Compliance, Stabilizing Listing Status - The Globe and Mail
Immunic regains Nasdaq minimum bid price compliance By Investing.com - Investing.com South Africa
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement - Sahm
Immunic, Inc. (IMUX) latest stock news and headlines - sg.finance.yahoo.com
Immunic Regains Nasdaq Compliance as IMUX Stock Maintains Minimum Bid Price Requirement - Minichart
Immunic regains Nasdaq minimum bid price compliance - Investing.com
Immunic Regains Nasdaq Minimum Bid Price Compliance After 20 Consecutive Business Days - TradingView
[8-K] IMMUNIC, INC. Reports Material Event - Stock Titan
Immunic AG / US4525EP1011 - AD HOC NEWS
Immunic appoints Jon Congleton to board of directors By Investing.com - Investing.com South Africa
IMUX: HC Wainwright & Co. Reiterates Buy Rating with $8 Target | - GuruFocus
Immunic (IMUX) director Jon Congleton files initial Form 3 - Stock Titan
Immunic Appoints Biopharma Leader Jon Congleton to Board, Advancing MS Therapy Toward Phase 3 Pivotal Readouts - Minichart
Small cap wrap: BioHarvest Sciences, American Resources, First Phosphate, Immunic... - Proactive financial news
Immunic Adds Veteran Biopharma Leader to Board - TipRanks
Immunic appoints biopharmaceutical executive Jon Congleton to board - Yahoo! Finance Canada
Immunic Appoints Jon Congleton To Board - citybiz
Immunic appoints Jon Congleton to board of directors - Investing.com
Biopharmaceutical company Immunic, Inc. recently announced the appointment of experienced industry executive Jon Congleton to its board of directors. - Bitget
Veteran biotech leader Jon Congleton joins Immunic (NASDAQ: IMUX) board - Stock Titan
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton - PR Newswire
Smart Money: Is Immunic Inc stock a good dividend stock2026 Geopolitical Influence & Verified Short-Term Plans - baoquankhu1.vn
Growth Review: Is Immunic Inc undervalued by DCF analysisMarket Movement Recap & Fast Gaining Stock Reports - baoquankhu1.vn
Pharma News: Whats next for Immunic Inc stock2026 Action & Fast Gaining Stock Reports - baoquankhu1.vn
Immunic Inc Stock Warning Signs - GuruFocus
Guggenheim initiates coverage of Immunic (IMUX) with buy recommendation - MSN
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):